The Potential Public Health Impact of Herpes Zoster Vaccination of People Aged ≥ 50 Years in Japan: Results of a ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2018-04-21

AUTHORS

Daisuke Watanabe, Akiko Mizukami, Katsiaryna Holl, Desmond Curran, Desirée Van Oorschot, Lijoy Varghese, Makoto Shiragami

ABSTRACT

INTRODUCTION: The aim of this study was to compare the public health impact of introducing two herpes zoster (HZ) vaccines into the vaccination programs for the Japanese population aged ≥ 50 years: a single-dose Varicella Vaccine Live (VVL) or a two-dose adjuvanted Recombinant Zoster Vaccine (RZV). METHODS: A multi-cohort static Markov model was developed to follow age cohorts (50-59, 60-69, 70-79 and ≥ 80 years) over their remaining lifetime. Japan-specific data inputs for the model were obtained from Japanese data sources. Age-stratified vaccine efficacy and waning rates were based on published clinical trial data. In the base-case analysis, vaccine coverage was assumed to be 40% for both vaccines, and compliance with second-dose of the RZV vaccine was set to 95%. RESULTS: Vaccination with RZV was projected to prevent approximately 3.3 million HZ cases, 692,000 cases of postherpetic neuralgia (PHN), and 281,000 cases of other complications, compared with the prevention of 0.8 million HZ cases, 216,000 PHN cases, and 57,000 other complications with vaccination with VVL. The number of individuals needed to vaccinate in order to prevent one HZ case ranged from 6 to 14 using RZV (depending on age and assumed second-dose compliance) and from 21 to 138 depending on age using VVL. By preventing a higher number of HZ cases and its complications, RZV vaccination led to fewer outpatient visits and hospitalizations than vaccination with VVL. CONCLUSION: Both vaccines had a positive public health impact compared to no vaccination, but due to its higher vaccine efficacy, RZV demonstrated a superior public health impact compared with VVL. FUNDING: GlaxoSmithKline Biologicals SA. More... »

PAGES

269-284

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s13555-018-0236-3

DOI

http://dx.doi.org/10.1007/s13555-018-0236-3

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1103520532

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/29680914


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1117", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Public Health and Health Services", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Dermatology, Aichi Medical University, 1-1 Yazakokarimata, Nagakute, Aichi Japan", 
          "id": "http://www.grid.ac/institutes/grid.411234.1", 
          "name": [
            "Department of Dermatology, Aichi Medical University, 1-1 Yazakokarimata, Nagakute, Aichi Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Watanabe", 
        "givenName": "Daisuke", 
        "id": "sg:person.0650746517.58", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0650746517.58"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "GSK, Akasaka Intercity AIR, 1-8-1, Akasaka, Minato-ku, Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.488295.a", 
          "name": [
            "GSK, Akasaka Intercity AIR, 1-8-1, Akasaka, Minato-ku, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mizukami", 
        "givenName": "Akiko", 
        "id": "sg:person.015363362373.27", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015363362373.27"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "GSK, Avenue Fleming 20, Wavre, Belgium", 
          "id": "http://www.grid.ac/institutes/grid.425090.a", 
          "name": [
            "GSK, Akasaka Intercity AIR, 1-8-1, Akasaka, Minato-ku, Tokyo, Japan", 
            "GSK, Avenue Fleming 20, Wavre, Belgium"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Holl", 
        "givenName": "Katsiaryna", 
        "id": "sg:person.01212644706.51", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01212644706.51"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "GSK, Avenue Fleming 20, Wavre, Belgium", 
          "id": "http://www.grid.ac/institutes/grid.425090.a", 
          "name": [
            "GSK, Avenue Fleming 20, Wavre, Belgium"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Curran", 
        "givenName": "Desmond", 
        "id": "sg:person.01244160330.28", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01244160330.28"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "GSK, Avenue Fleming 20, Wavre, Belgium", 
          "id": "http://www.grid.ac/institutes/grid.425090.a", 
          "name": [
            "GSK, Avenue Fleming 20, Wavre, Belgium"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Van Oorschot", 
        "givenName": "Desir\u00e9e", 
        "id": "sg:person.0606453467.31", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0606453467.31"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "GSK R&D-Asia-Pacific and North Asia, 8 Cross Street, #24-01 PWC Building, Singapore, 048424 Singapore", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "GSK R&D-Asia-Pacific and North Asia, 8 Cross Street, #24-01 PWC Building, Singapore, 048424 Singapore"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Varghese", 
        "givenName": "Lijoy", 
        "id": "sg:person.011161314345.29", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011161314345.29"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Faculty of Pharmaceutical Sciences, Teikyo Heisei University, 4-21-2, Nakano, Nakano-ku, Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.440938.2", 
          "name": [
            "Faculty of Pharmaceutical Sciences, Teikyo Heisei University, 4-21-2, Nakano, Nakano-ku, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Shiragami", 
        "givenName": "Makoto", 
        "id": "sg:person.01306104373.94", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01306104373.94"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1186/s12877-017-0420-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074211022", 
          "https://doi.org/10.1186/s12877-017-0420-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40261-017-0581-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1092445446", 
          "https://doi.org/10.1007/s40261-017-0581-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40801-017-0119-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1092125743", 
          "https://doi.org/10.1007/s40801-017-0119-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1472-6963-13-359", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045367790", 
          "https://doi.org/10.1186/1472-6963-13-359"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s12325-016-0355-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007916165", 
          "https://doi.org/10.1007/s12325-016-0355-0"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2018-04-21", 
    "datePublishedReg": "2018-04-21", 
    "description": "INTRODUCTION: The aim of this study was to compare the public health impact of introducing two herpes zoster (HZ) vaccines into the vaccination programs for the Japanese population aged\u2009\u2265\u200950\u00a0years: a single-dose Varicella Vaccine Live (VVL) or a two-dose adjuvanted Recombinant Zoster Vaccine (RZV).\nMETHODS: A multi-cohort static Markov model was developed to follow age cohorts (50-59, 60-69, 70-79 and\u2009\u2265\u200980\u00a0years) over their remaining lifetime. Japan-specific data inputs for the model were obtained from Japanese data sources. Age-stratified vaccine efficacy and waning rates were based on published clinical trial data. In the base-case analysis, vaccine coverage was assumed to be 40% for both vaccines, and compliance with second-dose of the RZV vaccine was set to 95%.\nRESULTS: Vaccination with RZV was projected to prevent approximately 3.3 million HZ cases, 692,000 cases of postherpetic neuralgia (PHN), and 281,000 cases of other complications, compared with the prevention of 0.8 million HZ cases, 216,000 PHN cases, and 57,000 other complications with vaccination with VVL. The number of individuals needed to vaccinate in order to prevent one HZ case ranged from 6 to 14 using RZV (depending on age and assumed second-dose compliance) and from 21 to 138 depending on age using VVL. By preventing a higher number of HZ cases and its complications, RZV vaccination led to fewer outpatient visits and hospitalizations than vaccination with VVL.\nCONCLUSION: Both vaccines had a positive public health impact compared to no vaccination, but due to its higher vaccine efficacy, RZV demonstrated a superior public health impact compared with VVL.\nFUNDING: GlaxoSmithKline Biologicals SA.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s13555-018-0236-3", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1047318", 
        "issn": [
          "2193-8210", 
          "2190-9172"
        ], 
        "name": "Dermatology and Therapy", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "8"
      }
    ], 
    "keywords": [
      "recombinant zoster vaccine", 
      "public health impact", 
      "HZ cases", 
      "zoster vaccine", 
      "postherpetic neuralgia", 
      "vaccine efficacy", 
      "health impacts", 
      "positive public health impact", 
      "herpes zoster vaccine", 
      "high vaccine efficacy", 
      "herpes zoster vaccination", 
      "potential public health impact", 
      "clinical trial data", 
      "static Markov model", 
      "base-case analysis", 
      "PHN cases", 
      "People Aged", 
      "zoster vaccination", 
      "vaccine coverage", 
      "outpatient visits", 
      "two-dose", 
      "vaccination program", 
      "vaccination", 
      "trial data", 
      "vaccine", 
      "complications", 
      "Japanese population", 
      "efficacy", 
      "age cohorts", 
      "higher number", 
      "neuralgia", 
      "hospitalization", 
      "cases", 
      "Markov model analysis", 
      "cohort", 
      "years", 
      "visits", 
      "prevention", 
      "number of individuals", 
      "age", 
      "Aged", 
      "model analysis", 
      "compliance", 
      "aim", 
      "population", 
      "live", 
      "individuals", 
      "impact", 
      "study", 
      "number", 
      "rate", 
      "analysis", 
      "program", 
      "data sources", 
      "data", 
      "SA", 
      "Japan", 
      "results", 
      "model", 
      "coverage", 
      "Markov model", 
      "source", 
      "order", 
      "input", 
      "data input", 
      "lifetime", 
      "single-dose Varicella Vaccine Live", 
      "VVL", 
      "Vaccine Live", 
      "multi-cohort static Markov model", 
      "Japan-specific data inputs", 
      "Japanese data sources", 
      "Age-stratified vaccine efficacy", 
      "RZV vaccine", 
      "superior public health impact", 
      "GlaxoSmithKline Biologicals SA", 
      "Biologicals SA"
    ], 
    "name": "The Potential Public Health Impact of Herpes Zoster Vaccination of People Aged \u2265 50 Years in Japan: Results of a Markov Model Analysis", 
    "pagination": "269-284", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1103520532"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s13555-018-0236-3"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "29680914"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s13555-018-0236-3", 
      "https://app.dimensions.ai/details/publication/pub.1103520532"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-11-01T18:32", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211101/entities/gbq_results/article/article_767.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s13555-018-0236-3"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s13555-018-0236-3'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s13555-018-0236-3'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s13555-018-0236-3'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s13555-018-0236-3'


 

This table displays all metadata directly associated to this object as RDF triples.

214 TRIPLES      22 PREDICATES      108 URIs      95 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s13555-018-0236-3 schema:about anzsrc-for:11
2 anzsrc-for:1117
3 schema:author N2dd5fd5a7fe947f185d1858a2ff6e2ec
4 schema:citation sg:pub.10.1007/s12325-016-0355-0
5 sg:pub.10.1007/s40261-017-0581-5
6 sg:pub.10.1007/s40801-017-0119-4
7 sg:pub.10.1186/1472-6963-13-359
8 sg:pub.10.1186/s12877-017-0420-9
9 schema:datePublished 2018-04-21
10 schema:datePublishedReg 2018-04-21
11 schema:description INTRODUCTION: The aim of this study was to compare the public health impact of introducing two herpes zoster (HZ) vaccines into the vaccination programs for the Japanese population aged ≥ 50 years: a single-dose Varicella Vaccine Live (VVL) or a two-dose adjuvanted Recombinant Zoster Vaccine (RZV). METHODS: A multi-cohort static Markov model was developed to follow age cohorts (50-59, 60-69, 70-79 and ≥ 80 years) over their remaining lifetime. Japan-specific data inputs for the model were obtained from Japanese data sources. Age-stratified vaccine efficacy and waning rates were based on published clinical trial data. In the base-case analysis, vaccine coverage was assumed to be 40% for both vaccines, and compliance with second-dose of the RZV vaccine was set to 95%. RESULTS: Vaccination with RZV was projected to prevent approximately 3.3 million HZ cases, 692,000 cases of postherpetic neuralgia (PHN), and 281,000 cases of other complications, compared with the prevention of 0.8 million HZ cases, 216,000 PHN cases, and 57,000 other complications with vaccination with VVL. The number of individuals needed to vaccinate in order to prevent one HZ case ranged from 6 to 14 using RZV (depending on age and assumed second-dose compliance) and from 21 to 138 depending on age using VVL. By preventing a higher number of HZ cases and its complications, RZV vaccination led to fewer outpatient visits and hospitalizations than vaccination with VVL. CONCLUSION: Both vaccines had a positive public health impact compared to no vaccination, but due to its higher vaccine efficacy, RZV demonstrated a superior public health impact compared with VVL. FUNDING: GlaxoSmithKline Biologicals SA.
12 schema:genre article
13 schema:inLanguage en
14 schema:isAccessibleForFree true
15 schema:isPartOf Na19151d24dbb4db8874ac5ccb805c98c
16 Nae09276531ee4d6a896d42452cd8504b
17 sg:journal.1047318
18 schema:keywords Age-stratified vaccine efficacy
19 Aged
20 Biologicals SA
21 GlaxoSmithKline Biologicals SA
22 HZ cases
23 Japan
24 Japan-specific data inputs
25 Japanese data sources
26 Japanese population
27 Markov model
28 Markov model analysis
29 PHN cases
30 People Aged
31 RZV vaccine
32 SA
33 VVL
34 Vaccine Live
35 age
36 age cohorts
37 aim
38 analysis
39 base-case analysis
40 cases
41 clinical trial data
42 cohort
43 compliance
44 complications
45 coverage
46 data
47 data input
48 data sources
49 efficacy
50 health impacts
51 herpes zoster vaccination
52 herpes zoster vaccine
53 high vaccine efficacy
54 higher number
55 hospitalization
56 impact
57 individuals
58 input
59 lifetime
60 live
61 model
62 model analysis
63 multi-cohort static Markov model
64 neuralgia
65 number
66 number of individuals
67 order
68 outpatient visits
69 population
70 positive public health impact
71 postherpetic neuralgia
72 potential public health impact
73 prevention
74 program
75 public health impact
76 rate
77 recombinant zoster vaccine
78 results
79 single-dose Varicella Vaccine Live
80 source
81 static Markov model
82 study
83 superior public health impact
84 trial data
85 two-dose
86 vaccination
87 vaccination program
88 vaccine
89 vaccine coverage
90 vaccine efficacy
91 visits
92 years
93 zoster vaccination
94 zoster vaccine
95 schema:name The Potential Public Health Impact of Herpes Zoster Vaccination of People Aged ≥ 50 Years in Japan: Results of a Markov Model Analysis
96 schema:pagination 269-284
97 schema:productId N13a78fa455604d0ea9ddb096f8e06eac
98 N496f321180ca4534b555dd264235812b
99 N96f30ae2334943f9898c2d019843e9b8
100 schema:sameAs https://app.dimensions.ai/details/publication/pub.1103520532
101 https://doi.org/10.1007/s13555-018-0236-3
102 schema:sdDatePublished 2021-11-01T18:32
103 schema:sdLicense https://scigraph.springernature.com/explorer/license/
104 schema:sdPublisher Nc91450ed44854044b8878a884cf84b77
105 schema:url https://doi.org/10.1007/s13555-018-0236-3
106 sgo:license sg:explorer/license/
107 sgo:sdDataset articles
108 rdf:type schema:ScholarlyArticle
109 N13a78fa455604d0ea9ddb096f8e06eac schema:name doi
110 schema:value 10.1007/s13555-018-0236-3
111 rdf:type schema:PropertyValue
112 N2dd5fd5a7fe947f185d1858a2ff6e2ec rdf:first sg:person.0650746517.58
113 rdf:rest Nbf50b78de418475daa3a460b890097ea
114 N496f321180ca4534b555dd264235812b schema:name dimensions_id
115 schema:value pub.1103520532
116 rdf:type schema:PropertyValue
117 N4e0ab6f8d0b6424e973f36e41d3a5c7e rdf:first sg:person.0606453467.31
118 rdf:rest Ncf88626910f74a30bc6ca3f2678ef42e
119 N8c8d0055f7764aee889df3fd1bcc5a59 rdf:first sg:person.01244160330.28
120 rdf:rest N4e0ab6f8d0b6424e973f36e41d3a5c7e
121 N96f30ae2334943f9898c2d019843e9b8 schema:name pubmed_id
122 schema:value 29680914
123 rdf:type schema:PropertyValue
124 Na19151d24dbb4db8874ac5ccb805c98c schema:issueNumber 2
125 rdf:type schema:PublicationIssue
126 Na436cfbc1606474d81b787a5acd022be rdf:first sg:person.01212644706.51
127 rdf:rest N8c8d0055f7764aee889df3fd1bcc5a59
128 Nae09276531ee4d6a896d42452cd8504b schema:volumeNumber 8
129 rdf:type schema:PublicationVolume
130 Nbf50b78de418475daa3a460b890097ea rdf:first sg:person.015363362373.27
131 rdf:rest Na436cfbc1606474d81b787a5acd022be
132 Nc91450ed44854044b8878a884cf84b77 schema:name Springer Nature - SN SciGraph project
133 rdf:type schema:Organization
134 Ncf88626910f74a30bc6ca3f2678ef42e rdf:first sg:person.011161314345.29
135 rdf:rest Nf713f652945942209de38a2db124e562
136 Nf713f652945942209de38a2db124e562 rdf:first sg:person.01306104373.94
137 rdf:rest rdf:nil
138 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
139 schema:name Medical and Health Sciences
140 rdf:type schema:DefinedTerm
141 anzsrc-for:1117 schema:inDefinedTermSet anzsrc-for:
142 schema:name Public Health and Health Services
143 rdf:type schema:DefinedTerm
144 sg:journal.1047318 schema:issn 2190-9172
145 2193-8210
146 schema:name Dermatology and Therapy
147 schema:publisher Springer Nature
148 rdf:type schema:Periodical
149 sg:person.011161314345.29 schema:affiliation grid-institutes:None
150 schema:familyName Varghese
151 schema:givenName Lijoy
152 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011161314345.29
153 rdf:type schema:Person
154 sg:person.01212644706.51 schema:affiliation grid-institutes:grid.425090.a
155 schema:familyName Holl
156 schema:givenName Katsiaryna
157 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01212644706.51
158 rdf:type schema:Person
159 sg:person.01244160330.28 schema:affiliation grid-institutes:grid.425090.a
160 schema:familyName Curran
161 schema:givenName Desmond
162 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01244160330.28
163 rdf:type schema:Person
164 sg:person.01306104373.94 schema:affiliation grid-institutes:grid.440938.2
165 schema:familyName Shiragami
166 schema:givenName Makoto
167 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01306104373.94
168 rdf:type schema:Person
169 sg:person.015363362373.27 schema:affiliation grid-institutes:grid.488295.a
170 schema:familyName Mizukami
171 schema:givenName Akiko
172 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015363362373.27
173 rdf:type schema:Person
174 sg:person.0606453467.31 schema:affiliation grid-institutes:grid.425090.a
175 schema:familyName Van Oorschot
176 schema:givenName Desirée
177 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0606453467.31
178 rdf:type schema:Person
179 sg:person.0650746517.58 schema:affiliation grid-institutes:grid.411234.1
180 schema:familyName Watanabe
181 schema:givenName Daisuke
182 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0650746517.58
183 rdf:type schema:Person
184 sg:pub.10.1007/s12325-016-0355-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007916165
185 https://doi.org/10.1007/s12325-016-0355-0
186 rdf:type schema:CreativeWork
187 sg:pub.10.1007/s40261-017-0581-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1092445446
188 https://doi.org/10.1007/s40261-017-0581-5
189 rdf:type schema:CreativeWork
190 sg:pub.10.1007/s40801-017-0119-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1092125743
191 https://doi.org/10.1007/s40801-017-0119-4
192 rdf:type schema:CreativeWork
193 sg:pub.10.1186/1472-6963-13-359 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045367790
194 https://doi.org/10.1186/1472-6963-13-359
195 rdf:type schema:CreativeWork
196 sg:pub.10.1186/s12877-017-0420-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074211022
197 https://doi.org/10.1186/s12877-017-0420-9
198 rdf:type schema:CreativeWork
199 grid-institutes:None schema:alternateName GSK R&D-Asia-Pacific and North Asia, 8 Cross Street, #24-01 PWC Building, Singapore, 048424 Singapore
200 schema:name GSK R&D-Asia-Pacific and North Asia, 8 Cross Street, #24-01 PWC Building, Singapore, 048424 Singapore
201 rdf:type schema:Organization
202 grid-institutes:grid.411234.1 schema:alternateName Department of Dermatology, Aichi Medical University, 1-1 Yazakokarimata, Nagakute, Aichi Japan
203 schema:name Department of Dermatology, Aichi Medical University, 1-1 Yazakokarimata, Nagakute, Aichi Japan
204 rdf:type schema:Organization
205 grid-institutes:grid.425090.a schema:alternateName GSK, Avenue Fleming 20, Wavre, Belgium
206 schema:name GSK, Akasaka Intercity AIR, 1-8-1, Akasaka, Minato-ku, Tokyo, Japan
207 GSK, Avenue Fleming 20, Wavre, Belgium
208 rdf:type schema:Organization
209 grid-institutes:grid.440938.2 schema:alternateName Faculty of Pharmaceutical Sciences, Teikyo Heisei University, 4-21-2, Nakano, Nakano-ku, Tokyo, Japan
210 schema:name Faculty of Pharmaceutical Sciences, Teikyo Heisei University, 4-21-2, Nakano, Nakano-ku, Tokyo, Japan
211 rdf:type schema:Organization
212 grid-institutes:grid.488295.a schema:alternateName GSK, Akasaka Intercity AIR, 1-8-1, Akasaka, Minato-ku, Tokyo, Japan
213 schema:name GSK, Akasaka Intercity AIR, 1-8-1, Akasaka, Minato-ku, Tokyo, Japan
214 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...